NetScientific PLC ProAxsis' ProteaseTagT research update (8155H)
03 Dezembro 2015 - 5:01AM
UK Regulatory
TIDMNSCI
RNS Number : 8155H
NetScientific PLC
03 December 2015
NetScientific plc
ProAxsis' ProteaseTag(TM) technology shown to effectively
monitor patients with
chronic obstructive pulmonary disease
London, UK - 3 December 2015 - Further to the announcement on 30
November 2015, NetScientific plc's (AIM: NSCI, "NetScientific" or
the "Group") portfolio company, ProAxsis, a medical diagnostics
spin-out from Queen's University Belfast, will present new data
today which validates the use of ProAxsis' ProteaseTag(TM) Active
Neutrophil Elastase (NE) Immunoassay in the monitoring of patients
with chronic obstructive pulmonary disease (COPD) for the first
time.
The results will be presented at the British Thoracic Society
Winter meeting in London at 2pm today and the full data can be
found on the ProAxsis website (www.proaxsis.com).
The data shows that ProAxsis' immunoassay can effectively
measure the level of active NE in sputum in COPD patients. A direct
correlation between high levels of active NE and exacerbations was
also identified. Previous work in the field has suggested that NE
levels start to rise two weeks before the clinical symptoms of an
exacerbation are apparent.
Key findings of the data include:
-- The study focused on a group of 10 COPD patients. The mean
level of active NE in sputum was measured at 217ng/ml when the
patient was experiencing an exacerbation. This was more than double
the mean level of 92ng/ml, in the same patients, when they were in
a stable phase of their disease.
-- In all cases, ProAxsis' immunoassay was effective in
measuring the level and changes in the levels of active NE prior to
and during exacerbations. The NE levels measured also correlated
appropriately with a number of other clinical markers of
inflammation.
The ProteaseTag(TM) technology traps active protease biomarkers
of diseases within a complex biological sample and provides a
visual readout of their presence. The ProteaseTag(TM) Active NE
Immunoassay measures only active NE, by selective capture coupled
with specific immunodetection. NE is an important drug target and
leading indicator of infection and inflammation in patients with
chronic respiratory diseases such as COPD and Cystic Fibrosis.
Dr David Ribeiro, CEO of ProAxsis, said: "Exacerbations in
chronic progressive respiratory diseases such as COPD can be very
damaging to a patient's long-term health and well-being as well as
creating a significant financial burden on the health service. COPD
exacerbations are a common cause of medical hospital admission in
the UK. They account for around one in eight hospital admissions
which costs the UK's National Health System over GBP250 million a
year.
"These promising results demonstrate the potential our assay has
to be developed as an early warning system for an impending
exacerbation. This would allow treatment to be taken earlier and
represents a significant step forward in the management of these
diseases."
NetScientific's Group CEO, Francois Martelet, M.D. commented:
"Millions of people have COPD but it is often not actively managed,
causing many health problems further down the line. These results
validate the use of ProAxsis' technology in the management of COPD
and represent a significant milestone for the company. ProAxsis
continues to make strong progress and will continue to work with
pharmaceutical and academic research groups focused on respiratory
diseases to further assess the immunoassay. We look forward to
working with ProAxsis to accelerate the development of this
exciting technology that has the potential to improve the active
monitoring of COPD and thus the lives of people all over the
world."
- Ends -
About NetScientific
NetScientific is a biomedical and healthcare technology group
that funds and develops technologies that offer transformative
benefits to people's lives and society through improved diagnosis,
prognosis and treatment.
For more information, please visit the website at
www.netscientific.net.
About ProAxsis
ProAxsis is developing a range of products for the capture,
detection and measurement of active protease biomarkers of
diseases. The rapid and easy-to-use tests incorporate patented
ProteaseTags(TM); smart molecules which trap an active protease
within a complex biological sample and enable a visual readout of
its presence. ProAxsis also offers customers a highly experienced
team that can provide clinical research services in regard to the
specific measurement of active proteases within clinical samples as
well as target validation.
The company was named one of Northern Ireland's most promising
companies in 2013. It is the only company in Northern Ireland, and
one of only a few in the UK, to have secured a prestigious Horizon
2020 SME Instrument Award. ProAxsis has also been highlighted as a
success story in Medical Research Council's 2014/15 Outputs,
Outcomes and Impact research report.
ProAxsis is part of the NetScientific group and is one of the
group's core portfolio companies. The company is also supported by
QUBIS, the commercialisation arm of Queens University. For more
information, please visit: www.proaxsis.com.
Contact Details
NetScientific Tel: +44 (0)20 3514 1800
François R. Martelet, M.D.,
CEO
Peter Thoms, CFO
Investec (NOMAD and broker) Tel: +44 (0)20 7597 4000
Gary Clarence / Daniel Adams
Instinctif Partners Tel: +44 (0)20 7457 2020
Melanie Toyne-Sewell / Jayne Crook Email: netscientific@instinctif.com
/ Rosanna Forrest
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESBXLBBELFBFBZ
(END) Dow Jones Newswires
December 03, 2015 02:01 ET (07:01 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024